Publication
PD-L1 expression and survival in unresectable/recurrent gastric cancer treated by 1st-line treatment without immune checkpoint inhibitors: JCOG1013A1.
Hidekazu Hirano, Yasuhide Yamada, Kengo Nagashima, Nobuyoshi Hiraoka, Shigeki Sekine, Naoki Takahashi, Mizutomo Azuma, Satoru Iwasa, Keisuke Kanato, Nozomu Machida, Takahiro Kinoshita, Hiroaki Hata, Hisato Kawakami, Daisuke Takahari, Toshiyasu Ojima, Shigenori Kadowaki, Narikazu Boku, Yukinori Kurokawa, Masanori Terashima, Takaki Yoshikawa
- Source
- PubMed
- Retrieved
- Sep 9, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260909-000004
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
BACKGROUND: The prognostic significance of PD-L1 expression in unresectable/recurrent gastric cancer treated by first-line chemotherapy without an immune checkpoint inhibitor (ICI) remains unclear. The phase III trial JCOG1013 demonstrated no overall survival (OS) or progression-free survival (PFS)…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Gastric Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available